-
Medical journals
- Career
Modulation of S1P in the Treatment of Autoimmune Diseases
We recommend
Long-term Safety and Efficacy of Ozanimod in the Treatment of Relapsing Forms of MS
28. 8. 2023 Source: Modulation of S1P in the Treatment of Autoimmune DiseasesOzanimod is classified as a modulator of sphingosine-1-phosphate (S1P) receptors types 1 and 5. It is approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) and moderate to severe ulcerative colitis (UC) and continues to undergo intensive clinical research. The DAYBREAK open-label, single-arm study for participants with RRMS from previous trials with ozanimod was scheduled to be completed by January 2023, and its final results can therefore be expected soon. The following article presents the interim analysis results…
Efficacy and Safety of Ozanimod in the Treatment of Relapsing-Remitting MS
The sphingosine-1-phosphate receptor (S1PR) modulator ozanimod has recently been approved for the…9. 5. 2023 Source: Modulation of S1P in the Treatment of Autoimmune Diseases
No content is currently available on this topic.LoginSubscribe
Conferences news
Go to records
Go to records
Most read on this topic- Efficacy and Safety of Ozanimod in the Treatment of Relapsing-Remitting MS
- Long-term Safety and Efficacy of Ozanimod in the Treatment of Relapsing Forms of MS
Journal on this topic
Related topic
Interesting linksLogin#ADS_BOTTOM_SCRIPTS#Forgotten passwordEnter the email address that you registered with. We will send you instructions on how to set a new password.
- Career